Your browser doesn't support javascript.
loading
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.
Helgadottir, Hildur; Ghiorzo, Paola; van Doorn, Remco; Puig, Susana; Levin, Max; Kefford, Richard; Lauss, Martin; Queirolo, Paola; Pastorino, Lorenza; Kapiteijn, Ellen; Potrony, Miriam; Carrera, Cristina; Olsson, Håkan; Höiom, Veronica; Jönsson, Göran.
Afiliação
  • Helgadottir H; Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
  • Ghiorzo P; Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • van Doorn R; Department of Dermatology, LUMC, Leiden, The Netherlands.
  • Puig S; Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Levin M; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
  • Kefford R; Department of Oncology, The Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
  • Lauss M; Department of Clinical Medicine, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia.
  • Queirolo P; Department of Oncology, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden.
  • Pastorino L; Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Kapiteijn E; Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Potrony M; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Carrera C; Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Olsson H; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
  • Höiom V; Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Jönsson G; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain.
J Med Genet ; 57(5): 316-321, 2020 05.
Article em En | MEDLINE | ID: mdl-30291219
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidor p16 de Quinase Dependente de Ciclina / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Med Genet Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidor p16 de Quinase Dependente de Ciclina / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Med Genet Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia